Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models

Nanni Schmitt, Alexander Streuer, Justine Danner, Eva Altrock, Vladimir Riabov, Qingyu Xu, Felicitas Rapp, Nadine Weimer, Iris Palme, Verena Nowak, Julia Obländer, Melda Göl, Ali Darwich, Laurenz Steiner, Tobias Boch, Mohamad Jawhar, Georgia Metzgeroth, Wolf-Karsten Hofmann, Daniel Nowak

Blood (2022) 140 (Supplement 1): 4009–4010.

https://doi.org/10.1182/blood-2022-168709

Published: 2022

Journal Articles

ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 9749–9750.

https://doi.org/10.1182/blood-2022-165298

Published: 2022

Journal Articles

Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 3054–3055.

https://doi.org/10.1182/blood-2022-159507

Published: 2022

Journal Articles

Preclinical Assessment of Alvocidib in Combination with 5-Azacytidine in High-Risk Myelodysplastic Syndromes

Vladimir Riabov, Qingyu Xu, Nanni Schmitt, Alexander Streuer, Johann-Christoph Jann, Alina Wein, Eva Altrock, Arwin Mehralivand, Verena Nowak, Nadine Weimer, Julia Obländer, Iris Palme, Mohamad Jawhar, Christel Weiss, Georgia Metzgeroth, Jason M Foulks, Wolf-Karsten Hofmann, Daniel Nowak

Blood (2021) 138 (Supplement 1): 4649.

https://doi.org/10.1182/blood-2021-150778

Published: 2021

Journal Articles

Mesenchymal Stromal Cells (MSCs) from Myelodysplastic Syndromes (MDS) Are Not Clonally Mutated I n Vivo

Johann-Christoph Jann, Maximilian Mossner, Vladimir Riabov, Eva Altrock, Nanni Schmitt, Johanna Flach, Qingyu Xu, Verena Nowak, Julia Obländer, Iris Palme, Nadine Weimer, Alexander Streuer, Ahmed Jawhar, Ali Darwich, Georgia Metzgeroth, Florian Nolte, Wolf-Karsten Hofmann, Daniel Nowak

Blood (2021) 138 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2021-150244

Published: 2021

Journal Articles

Comparison of Four Different Humanized Hematopoietic Niche Xenotransplantation Methods to Engraft Myelodysplastic Syndromes (MDS)

Blood (2019) 134 (Supplement_1): 4227.

https://doi.org/10.1182/blood-2019-128075

Published: 2019

Journal Articles

R-Loops-Induced ATR Signaling As a Potential Therapeutic Target in Myelodysplastic Syndrome

Johann-Christoph Jann, Johanna Flach, PhD, Antje Knaflic, Eva Altrock, PhD, Nanni Schmitt, MSc, Alexander Streuer, Justine Danner, Franziska Hofmann, Verena Nowak, Nina Draeger, Julia Obländer, Iris Palme, Patrick Wuchter, MD, Ahmed Jawhar, MD, Georgia Metzgeroth, MD, Florian Nolte, MD, Wolf-Karsten Hofmann, MD PhD, Daniel Nowak, MD

Blood (2019) 134 (Supplement_1): 4218.

https://doi.org/10.1182/blood-2019-126431

Published: 2019

Journal Articles

Placebo Controlled Functional Analysis of Eltrombopag in a Preclinical Xenograft Model of Myelodysplastic Syndromes (MDS)

Nanni Schmitt, MSc, Eva Altrock, PhD, Johann-Christoph Jann, MD, Johanna Flach, PhD, Carla Sens-Albert, PhD, Justine Danner, Stefanie Uhlig, Jovita Pressler, Iris Palme, Verena Nowak, Julia Obländer, Lena Drangmeister, MD, Franziska La Meir, MD, Georgia Metzgeroth, MD, Florian Nolte, MD, Wolf-Karsten Hofmann, Daniel Nowak, MD

Blood (2018) 132 (Supplement 1): 942.

https://doi.org/10.1182/blood-2018-99-116341

Published: 2018

Journal Articles

Genomic CDKN2A/2B deletions in adult Ph + ALL are adverse despite allogeneic stem cell transplantation

Blood (2018) 131 (13): 1464–1475.

https://doi.org/10.1182/blood-2017-07-796862

Published: 2018

Includes: Supplemental data

Journal Articles

RNA Sequencing of Bone Marrow Derived Mesenchymal Stromal Cells (MSCs) of Healthy Young, Healthy Old and Patients with Myelodysplastic Syndrome (MDS) Reveals Transcriptomic Changes upon Aging of the Niche and Onset of MDS

Johann-Christoph Jann, Maximilian Mossner, Florian Nolte, MD, Tobias Boch, MD, Verena Nowak, Iris Palme, Julia Obländer, Jovita Pressler, Christina Xanthopoulos, Henning Röhl, MD, Wolf-Karsten Hofmann, MD, Daniel Nowak, MD

Blood (2016) 128 (22): 4300.

https://doi.org/10.1182/blood.V128.22.4300.4300

Published: 2016

Journal Articles

Validation of a Molecular Risk Score for Prognosis of Patients with Acute Promyelocytic Leukemia

Anna Hecht, MD, Seraphina Doll, Heidi Schaarschmidt, Daniel Nowak, MD, Verena Nowak, Julia Obländer, Christina Xanthopoulos, Eva Lengfelder, MD, Christoph Röllig, MD, Gerhard Ehninger, MD, Wolf-Karsten Hofmann, MD, Uwe Platzbecker

Blood (2016) 128 (22): 1668.

https://doi.org/10.1182/blood.V128.22.1668.1668

Published: 2016

Journal Articles

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

Blood (2016) 128 (9): 1246–1259.

https://doi.org/10.1182/blood-2015-11-679167

Published: 2016

Includes: Supplemental data

Journal Articles

Whole Genome Sequencing of Azole-Resistant Aspergillus Fumigatus Strains from Hematopoietic Stem Cell Recipients Identifies Candidate Molecular Targets Potentially Implicated in Novel Resistance Mediating Mechanisms - First Results

Maximilian Mossner, Birgit Spiess, PhD, Johann-Christoph Jann, Verena Nowak, Julia Obländer, Oliver Bader, Wolf-Karsten Hofmann, MD, Daniel Nowak, MD, Dieter Buchheidt, MD, Tobias Boch, MD

Blood (2015) 126 (23): 4325.

https://doi.org/10.1182/blood.V126.23.4325.4325

Published: 2015

Journal Articles

Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial

Blood (2014) 124 (21): 1920.

https://doi.org/10.1182/blood.V124.21.1920.1920

Published: 2014

Journal Articles

Development of a DNA-Based Targeted Assay Suitable for Accurate Quantification of Chromosomal Deletions in Myelodysplastic Syndromes with Deletion (5q) and Other Clonal Diseases

Johann-Christoph Jann, Daniel Nowak, Florian Nolte, Stephanie Fey, Verena Nowak, Julia Obländer, Jovita Pressler, Alice Fabarius, PhD, Claudia Haferlach, MD, Hind Medyouf, PhD, Wolf-Karsten Hofmann, Maximilian Mossner

Blood (2014) 124 (21): 1925.

https://doi.org/10.1182/blood.V124.21.1925.1925

Published: 2014

Journal Articles

Quantitative Analysis of Patient-Specific Lesions in Primary and Xenografted Myelodysplastic Syndromes Reveals Complex Hierarchies and Subclonal Diversity That Evolve during Disease Progression

Blood (2014) 124 (21): 4604.

https://doi.org/10.1182/blood.V124.21.4604.4604

Published: 2014

Journal Articles

Gene Expression of the Erythroid Regulator Erythroferrone (ERFE) is Highly Deregulated in CD71+ Erythroprogenitor Cells of Patients with Myelodysplastic Syndromes and Demonstrates Prognostic Relevance

Maximilian Mossner, Alexandra Stöhr, Florian Nolte, Johann-Christoph Jann, Stephanie Fey, Verena Nowak, Julia Obländer, Jovita Pressler, Claudia D Baldus, Torsten J Schulze, MD, Martin Neumann, MD, Wolf-Karsten Hofmann, Daniel Nowak

Blood (2014) 124 (21): 4620.

https://doi.org/10.1182/blood.V124.21.4620.4620

Published: 2014

Journal Articles

The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study

Evi launiger-Lörsch, Thomas Luft, Stephanie Fey, Julia Obländer, Susanne Brendel, Jovita Pressler, Johann-Christoph Jann, Claudia Kunz, Anthony D. Ho, Harald Fricke, Maximilian Mossner, Georgia Metzgeroth, Daniel Nowak, Wolf-Karsten Hofmann, Florian Nolte

Blood (2014) 124 (21): 4669.

https://doi.org/10.1182/blood.V124.21.4669.4669

Published: 2014

Journal Articles

TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial

Blood (2013) 122 (21): 2759.

https://doi.org/10.1182/blood.V122.21.2759.2759

Published: 2013

Journal Articles

MDS-Derived Stromal Cells Exhibit Altered Gene Expression and Support The Engraftment Of lin - CD34 + CD38 - Disease-Initiating Stem Cells In a Xenograft Model Of Lower Risk MDS

Blood (2013) 122 (21): 100.

https://doi.org/10.1182/blood.V122.21.100.100

Published: 2013

NARROW

Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models

ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms

Preclinical Assessment of Alvocidib in Combination with 5-Azacytidine in High-Risk Myelodysplastic Syndromes

Mesenchymal Stromal Cells (MSCs) from Myelodysplastic Syndromes (MDS) Are Not Clonally Mutated I n Vivo

Comparison of Four Different Humanized Hematopoietic Niche Xenotransplantation Methods to Engraft Myelodysplastic Syndromes (MDS)

R-Loops-Induced ATR Signaling As a Potential Therapeutic Target in Myelodysplastic Syndrome

Placebo Controlled Functional Analysis of Eltrombopag in a Preclinical Xenograft Model of Myelodysplastic Syndromes (MDS)

Genomic CDKN2A/2B deletions in adult Ph + ALL are adverse despite allogeneic stem cell transplantation

RNA Sequencing of Bone Marrow Derived Mesenchymal Stromal Cells (MSCs) of Healthy Young, Healthy Old and Patients with Myelodysplastic Syndrome (MDS) Reveals Transcriptomic Changes upon Aging of the Niche and Onset of MDS

Validation of a Molecular Risk Score for Prognosis of Patients with Acute Promyelocytic Leukemia

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

Whole Genome Sequencing of Azole-Resistant Aspergillus Fumigatus Strains from Hematopoietic Stem Cell Recipients Identifies Candidate Molecular Targets Potentially Implicated in Novel Resistance Mediating Mechanisms - First Results

Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial

Development of a DNA-Based Targeted Assay Suitable for Accurate Quantification of Chromosomal Deletions in Myelodysplastic Syndromes with Deletion (5q) and Other Clonal Diseases

Quantitative Analysis of Patient-Specific Lesions in Primary and Xenografted Myelodysplastic Syndromes Reveals Complex Hierarchies and Subclonal Diversity That Evolve during Disease Progression

Gene Expression of the Erythroid Regulator Erythroferrone (ERFE) is Highly Deregulated in CD71+ Erythroprogenitor Cells of Patients with Myelodysplastic Syndromes and Demonstrates Prognostic Relevance

The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study

TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial

MDS-Derived Stromal Cells Exhibit Altered Gene Expression and Support The Engraftment Of lin - CD34 + CD38 - Disease-Initiating Stem Cells In a Xenograft Model Of Lower Risk MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only